Legend Biotech Corp - Asset Resilience Ratio
Legend Biotech Corp (LEGN) has an Asset Resilience Ratio of 2.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Legend Biotech Corp assets under control for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Legend Biotech Corp's Asset Resilience Ratio has changed over time. See net asset quality index of Legend Biotech Corp to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Legend Biotech Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Legend Biotech Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $46.70 Million | 2.69% |
| Total Liquid Assets | $46.70 Million | 2.69% |
Asset Resilience Insights
- Limited Liquidity: Legend Biotech Corp maintains only 2.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Legend Biotech Corp Industry Peers by Asset Resilience Ratio
Compare Legend Biotech Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Legend Biotech Corp (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Legend Biotech Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.69% | $46.70 Million | $1.73 Billion | -47.36pp |
| 2024-12-31 | 50.05% | $835.93 Million | $1.67 Billion | +48.37pp |
| 2023-12-31 | 1.68% | $31.00 Million | $1.85 Billion | -16.33pp |
| 2022-12-31 | 18.00% | $239.62 Million | $1.33 Billion | +0.72pp |
| 2021-12-31 | 17.28% | $193.46 Million | $1.12 Billion | +10.36pp |
| 2020-12-31 | 6.92% | $50.00 Million | $722.09 Million | -19.34pp |
| 2019-12-31 | 26.26% | $75.56 Million | $287.71 Million | +24.86pp |
| 2018-12-31 | 1.40% | $6.01 Million | $429.05 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more